cDNA accession Links to the sequence |
Tissue most 5' clones in red |
Match mRNA |
From bp to bp in mRNA |
From bp to bp in accs. |
Clone encodes complete protein (with AA variation) |
Features | Anomalies detected by AceView |
Accession match over (% length) |
Base differences relative to genome (% identity) |
AA093176 | .f | 778 to 1050 | 1 to 263 | tiling clone, AAA | 263/314 (83 %) | 12 diff (96.2 %id) | |||
AB185926 | .c | 1 to 2687 | 1 to 2687 | I640N | tiling clone, | 2687/2688 (99 %) | 7 diff (99.8 %id) | ||
AB185927 | .a | 1 to 2278 | 1 to 2278 | exact | tiling clone, | 2278/2279 (99 %) | 2 diff (100.0 %id) | ||
AF108138 | .d | 1 to 1786 | 1 to 1786 | I373N | tiling clone, AAA | Possibly primed on the genome, locally A rich (24/24 A in genome downstream of last aligned base) | 1786/1786 (100 %) | 4 diff (99.8 %id) | |
AK026345 | human small intestine | .e | 1 to 1631 | 1 to 1631 | exact | tiling clone, available from FLJ, AAA | Possibly primed on the genome, locally A rich (24/24 A in genome downstream of last aligned base) | 1631/1631 (100 %) | 2 diff (99.9 %id) |
AW801494 | uterus | .a | 1534 to 1951 | 419 to 3 | 417/419 (99 %) | 0 diff (100 %id) | |||
AY498716 | .c | 77 to 2682 | 1 to 2606 | I640N | tiling clone, | 2606/2606 (100 %) | 4 diff (99.9 %id) | ||
BC137503 | Testicle, PCR rescued clones | .c | 63 to 2453 | 1 to 2391 | exact | tiling clone, | 2391/2391 (100 %) | 3 diff (99.9 %id) | |
BC137504 | Brain, cerebral cortex, PCR rescued clones | .c | 63 to 2453 | 1 to 2391 | exact | 2391/2391 (100 %) | 3 diff (99.9 %id) | ||
TI_1971555299 | .c | 1422 to 2453 | 1105 to 72 | 1034/1316 (78 %) | 12 diff (99.1 %id) | ||||
TI_1971556307 | .c | 1179 to 2371 | 1194 to 11 | 1184/1280 (92 %) | 22 diff (98.3 %id) | ||||
TI_1971556321 | .a | 715 to 1859 | 19 to 1170 | 1152/1335 (86 %) | 21 diff (98.5 %id) | ||||
TI_1971556329 | .c | 1218 to 2383 | 22 to 1182 | 1161/1286 (90 %) | 21 diff (98.4 %id) | ||||
TI_1971558149 | .a | 60 to 652 | 48 to 639 | 592/639 (92 %) | 6 diff (99.1 %id) | ||||
BG951026 | colon | .l-u | 112 to 721 | 27 to 632 | tiling clone, | 606/632 (95 %) | 6 diff (99.1 %id) | ||
BM888249 | eye | .l-u | 236 to 830 | 1 to 589 | R41S L42W G43V A44Q A45P ... | 589/589 (100 %) | 12 diff (98.0 %id) | ||
BQ315498 | epid_tumor | .a | 684 to 856 | 179 to 6 | 174/179 (97 %) | 2 diff (98.9 %id) | |||
BX109827 | liver and spleen | .l-u | 373 to 833 | 1 to 461 | R24S | AAA | Possibly primed on the genome, locally A rich (24/24 A in genome downstream of last aligned base) | 461/461 (100 %) | 2 diff (99.6 %id) |
BX283578 | choriocarcinoma, placenta | .a | 51 to 556 | 25 to 529 | 505/529 (95 %) | 7 diff (98.7 %id) | |||
CN259034 | embryonic stem cells, DMSO-treated H9 cellline | .n-u | 1 to 636 | 1 to 636 | exact | tiling clone, | 636/636 (100 %) | 3 diff (99.6 %id) | |
CN259035 | embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells | .a | 59 to 184 | 7 to 132 | 126/132 (95 %) | 0 diff (100 %id) | |||
CN259036 | embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells | .a | 83 to 355 | 1 to 273 | 273/273 (100 %) | 1 diff (99.7 %id) | |||
CN259037 | embryonic stem cells, cell lines H1, H7, andH9 | .a | 30 to 314 | 1 to 285 | 285/285 (100 %) | 4 diff (98.6 %id) | |||
CN265097 | embryonic stem cells, cell lines H1, H7, andH9 | .a | 931 to 1078 | 1 to 148 | 148/148 (100 %) | 2 diff (98.7 %id) | |||
CN277199 | embryonic stem cells, DMSO-treated H9 cellline | .f | 1068 to 1475 | 1 to 407 | tiling clone, | 407/407 (100 %) | 2 diff (99.6 %id) | ||
CN358868 | embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 | .a | 1123 to 1822 | 1 to 701 | 701/701 (100 %) | 2 diff (99.8 %id) | |||
CN358869 | embryonic stem cells, cell lines H1, H7, andH9 | .m | 204 to 662 | 7 to 465 | exact | tiling clone, | 459/465 (98 %) | 6 diff (98.8 %id) | |
CN358870 | embryonic stem cells, cell lines H1, H7, andH9 | .k | 1 to 653 | 1 to 653 | tiling clone, | 653/653 (100 %) | 2 diff (99.7 %id) | ||
CN358871 | embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells | .k | 448 to 759 | 1 to 312 | exact | tiling clone, | 312/312 (100 %) | 0 diff (100 %id) | |
CR738883 | liver and spleen | .l-u | 373 to 833 | 1 to 461 | R24S | AAA | Possibly primed on the genome, locally A rich (24/24 A in genome downstream of last aligned base) | 461/461 (100 %) | 2 diff (99.6 %id) |
DN930402 | pooled | .a | 1408 to 1667 | 261 to 1 | Submitted on the opposite strand | 261/261 (100 %) | 1 diff (99.7 %id) | ||
DQ437529 | .c | 96 to 2147 | 1 to 2052 | exact | 2052/2052 (100 %) | 3 diff (99.9 %id) | |||
DW424379 | Liver | .m | 1 to 268 | 22 to 289 | tiling clone, | 268/289 (92 %) | 8 diff (97.3 %id) | ||
ES309570 | occipital hair of pubic hypotrichosispatient, skin | .a | 1446 to 1910 | 19 to 471 | 453/555 (81 %) | 17 diff (97.0 %id) | |||
EU084033 | .b | 1 to 2682 | 1 to 2682 | exact | tiling clone, | 2682/2682 (100 %) | 3 diff (99.9 %id) | ||
BP420945 | small intestine | .g | 47 to 550 | 1 to 505 | Submitted on the opposite strand | 505/505 (100 %) | 4 diff (99.3 %id) | ||
T54683 | fetal spleen, Spleen | .l-u | 410 to 784 | 1 to 388 | T57Y A58S R59* | 388/392 (98 %) | 22 diff (94.4 %id) | ||
T88870 | liver and spleen | .l-u | 382 to 838 | 462 to 2 | S12L F13L Q14S A15G A16C ... | 461/464 (99 %) | 0 diff (100 %id) | ||
W60651 | heart | .l-u | 518 to 833 | 359 to 41 | fully sequenced, AAA | Possibly primed on the genome, locally A rich (24/24 A in genome downstream of last aligned base) | 319/319 (100 %) | 2 diff (99.4 %id) | |
W60880 | heart | .l-u | 434 to 833 | 1 to 399 | S46P K47N Q48R R49E T50R ... | fully sequenced, | Possibly primed on the genome, locally A rich (24/24 A in genome downstream of last aligned base) | 399/399 (100 %) | 5 diff (98.8 %id) |
AA278838 | germinal center B cell | .l-u | 479 to 838 | 363 to 3 | A58G R59* | tiling clone, fully sequenced, | 361/363 (99 %) | 0 diff (100 %id) | |
AA279102 | germinal center B cell | .l-u | 1 to 503 | 1 to 499 | tiling clone, fully sequenced, | 499/499 (100 %) | 3 diff (99.4 %id) | ||
AA464521 | ovarian tumor, ovary | .c | 1660 to 2168 | 1 to 492 | 492/495 (99 %) | 21 diff (95.8 %id) | |||
AA464522 | ovarian tumor, ovary | .c | 2253 to 2682 | 432 to 1 | 432/432 (100 %) | 7 diff (98.4 %id) | |||
AA642924 | epithelium (cell line), Prostate | .a | 2096 to 2273 | 194 to 17 | AAA | Possibly primed on the genome, locally A rich (24/24 A in genome downstream of last aligned base) | 178/179 (99 %) | 0 diff (100 %id) | |
AA743647 | germinal center B cell | .l-u | 364 to 833 | 481 to 11 | A58S R59* | AAA | Possibly primed on the genome, locally A rich (24/24 A in genome downstream of last aligned base) | 471/471 (100 %) | 2 diff (99.6 %id) |
AA872541 | germinal center B cell | .a | 1998 to 2273 | 286 to 12 | AAA | Possibly primed on the genome, locally A rich (24/24 A in genome downstream of last aligned base) | 275/275 (100 %) | 1 diff (99.7 %id) | |
AA827755 | germinal center B cell | .a | 318 to 787 | 1 to 467 | Submitted on the opposite strand | 467/467 (100 %) | 17 diff (96.4 %id) | ||
AA973831 | pooled germ cell tumors | .f | 1092 to 1376 | 294 to 11 | tiling clone, | 284/294 (96 %) | 0 diff (100 %id) | ||
AI333976 | mixed (see below), Pooled human melanocyte, fetal heart, andpregnant uterus | .l-u | 366 to 837 | 471 to 1 | S12P Q14R A15L A16Q E17K ... | 471/471 (100 %) | 1 diff (99.8 %id) | ||
AI280491 | ovary, tumor, 5 pooled (see description) | .a | 1962 to 2273 | 312 to 1 | 312/315 (99 %) | 0 diff (100 %id) | |||
AI889087 | colon, colon tumor, RER+ | .a | 101 to 294 | 194 to 1 | 194/194 (100 %) | 2 diff (99.0 %id) | |||
AI654749 | ovary, tumor, 5 pooled (see description) | .l-u | 417 to 833 | 417 to 1 | S12P | 417/417 (100 %) | 2 diff (99.6 %id) | ||
AI745642 | ovary, tumor, 5 pooled (see description) | .l-u | 438 to 834 | 397 to 1 | exact | 397/397 (100 %) | 0 diff (100 %id) | ||
AI655645 | pooled germ cell tumors | .l-u | 353 to 833 | 481 to 1 | exact | 481/481 (100 %) | 0 diff (100 %id) | ||
AI696210 | pooled germ cell tumors | .a | 1958 to 2273 | 315 to 1 | 315/315 (100 %) | 1 diff (99.7 %id) | |||
AI827264 | lung, squamous cell carcinoma, poorlydifferentiated (4 pooled tumors, including primary andmetastatic) | .a | 2003 to 2273 | 286 to 16 | AAA | Possibly primed on the genome, locally A rich (24/24 A in genome downstream of last aligned base) | 271/271 (100 %) | 3 diff (98.9 %id) | |
AW004048 | pooled germ cell tumors | .l-u | 283 to 833 | 562 to 12 | exact | AAA | Possibly primed on the genome, locally A rich (24/24 A in genome downstream of last aligned base) | 551/551 (100 %) | 0 diff (100 %id) |
AI984536 | colon, colonic mucosa from 3 patients with Crohn'sdisease | .l-u | 399 to 836 | 438 to 1 | exact | 438/438 (100 %) | 1 diff (99.8 %id) | ||
AW170361 | cervix, tumor | .l-u | 285 to 840 | 562 to 6 | L52F S56F | 557/562 (99 %) | 0 diff (100 %id) | ||
AW590310 | pooled germ cell tumors | .l-u | 341 to 837 | 497 to 1 | exact | 497/497 (100 %) | 0 diff (100 %id) | ||
AW663962 | pooled | .l-u | 359 to 834 | 477 to 2 | G27A A58V | 476/477 (99 %) | 0 diff (100 %id) | ||
BF516453 | .l-u | 392 to 833 | 459 to 18 | exact | AAA | Possibly primed on the genome, locally A rich (24/24 A in genome downstream of last aligned base) | 442/442 (100 %) | 1 diff (99.8 %id) | |
CF137126 | lymph | .e | 1129 to 1612 | 1 to 484 | 484/486 (99 %) | 4 diff (99.2 %id) | |||
BC018978 | Placenta, choriocarcinoma | .f | 1 to 1114 | 1 to 1114 | exact | tiling clone, available from MGC, AAA | Possibly primed on the genome, locally A rich (12/12 A in genome downstream of last aligned base) | 1114/1114 (100 %) | 2 diff (99.9 %id) |
BE280562 | choriocarcinoma, placenta | .a | 71 to 632 | 1 to 563 | available from MGC, | 563/563 (100 %) | 7 diff (98.8 %id) | ||
BE387734 | endometrium, adenocarcinoma cell line, uterus | .e | 990 to 1631 | 1 to 641 | AAA | Possibly primed on the genome, locally A rich (24/24 A in genome downstream of last aligned base) | 641/641 (100 %) | 2 diff (99.7 %id) | |
BF316643 | brain, neuroblastoma | .a | 71 to 784 | 1 to 703 | 703/978 (71 %) | 36 diff (96.4 %id) | |||
BG231673 | blood, lymphocyte | .l-u | 349 to 832 | 484 to 1 | exact | 484/484 (100 %) | 0 diff (100 %id) | ||
BG323851 | Kidney, renal cell adenocarcinoma | .a | 122 to 744 | 1 to 624 | 624/624 (100 %) | 26 diff (95.9 %id) | |||
BI116535 | lung, small cell carcinoma | .h | 1 to 693 | 1 to 694 | W155S R156E Q157A A158G D159R ... | tiling clone, | 694/695 (99 %) | 7 diff (99.0 %id) | |
BC033254 | Prostate, carcinoma | .g | 2 to 1548 | 1 to 1547 | I188N | tiling clone, available from MGC, AAA | Possibly primed on the genome, locally A rich (24/24 A in genome downstream of last aligned base) | 1547/1547 (100 %) | 1 diff (100.0 %id) |
BM043514 | carcinoma, cell line, Prostate | .g | 1 to 644 | 1 to 646 | tiling clone, available from MGC, | 646/796 (81 %) | 22 diff (97.3 %id) | ||
BQ061682 | lymph, lymphoma, cell line | .j | 1 to 881 | 1 to 886 | M12Y D13G S14Q N15Q E17* | tiling clone, | 886/971 (91 %) | 17 diff (98.3 %id) | |
BQ065272 | lymph, lymphoma, cell line | .j | 1 to 670 | 1 to 673 | exact | tiling clone, | 673/1188 (56 %) | 9 diff (99.3 %id) | |
BU502486 | carcinoma, cell line, Prostate | .g | 23 to 568 | 90 to 641 | 552/1264 (43 %) | 30 diff (97.7 %id) | |||
BQ958807 | carcinoma, cell line, Prostate | .g | 3 to 811 | 1 to 820 | 820/876 (93 %) | 13 diff (98.6 %id) | |||
NM_025049.2 | .c | 30 to 2688 | 1 to 2659 | exact | RefSeq, | 2659/2659 (100 %) | 1 diff (100.0 %id) | ||
DA997599 | .a | 426 to 813 | 2 to 389 | capped | 388/388 (100 %) | 1 diff (99.8 %id) | |||
DN998093 | breast cancer, Mammary gland (cancer tissue) | .i | 1 to 673 | 8 to 680 | exact | tiling clone, | 673/680 (98 %) | 6 diff (99.2 %id) | |
DN999504 | .a | 65 to 630 | 12 to 577 | 566/577 (98 %) | 6 diff (99.0 %id) | ||||
TI_154166449 | .e | 1136 to 1632 | 93 to 590 | 498/953 (52 %) | 5 diff (99.5 %id) | ||||
CA310274 | Alveolar Macrophage, lung | .l-u | 184 to 833 | 665 to 16 | exact | tiling clone, AAA | Possibly primed on the genome, locally A rich (24/24 A in genome downstream of last aligned base) | 650/651 (99 %) | 3 diff (99.6 %id) |
AI652391 | pooled germ cell tumors | .a | 71 to 784 | 1 to 703 | Suspected internal deletion, this clone was ignored | 703/978 (71 %) | 36 diff (96.4 %id) | ||
BF316643 | brain, neuroblastoma | .a | 71 to 784 | 1 to 703 | 703/978 (71 %) | 36 diff (96.4 %id) | |||
BG231673 | blood, lymphocyte | .l-u | 349 to 832 | 484 to 1 | exact | 484/484 (100 %) | 0 diff (100 %id) | ||
BG231673 | blood, lymphocyte | .l-u | 349 to 832 | 484 to 1 | exact | 484/484 (100 %) | 0 diff (100 %id) | ||
BG323851 | Kidney, renal cell adenocarcinoma | .a | 122 to 744 | 1 to 624 | 624/624 (100 %) | 26 diff (95.9 %id) | |||
BG323851 | Kidney, renal cell adenocarcinoma | .a | 122 to 744 | 1 to 624 | 624/624 (100 %) | 26 diff (95.9 %id) | |||
BI116535 | lung, small cell carcinoma | .h | 1 to 693 | 1 to 694 | W155S R156E Q157A A158G D159R ... | tiling clone, | 694/695 (99 %) | 7 diff (99.0 %id) | |
BI116535 | lung, small cell carcinoma | .h | 1 to 693 | 1 to 694 | W155S R156E Q157A A158G D159R ... | tiling clone, | 694/695 (99 %) | 7 diff (99.0 %id) | |
BC033254 | Prostate, carcinoma | .g | 2 to 1548 | 1 to 1547 | I188N | tiling clone, available from MGC, AAA | Possibly primed on the genome, locally A rich (24/24 A in genome downstream of last aligned base) | 1547/1547 (100 %) | 1 diff (100.0 %id) |
BM043514 | carcinoma, cell line, Prostate | .g | 1 to 644 | 1 to 646 | tiling clone, available from MGC, | 646/796 (81 %) | 22 diff (97.3 %id) | ||
BM043514 | carcinoma, cell line, Prostate | .g | 1 to 644 | 1 to 646 | tiling clone, available from MGC, | 646/796 (81 %) | 22 diff (97.3 %id) | ||
BQ061682 | lymph, lymphoma, cell line | .j | 1 to 881 | 1 to 886 | M12Y D13G S14Q N15Q E17* | tiling clone, | 886/971 (91 %) | 17 diff (98.3 %id) | |
BQ061682 | lymph, lymphoma, cell line | .j | 1 to 881 | 1 to 886 | M12Y D13G S14Q N15Q E17* | tiling clone, | 886/971 (91 %) | 17 diff (98.3 %id) | |
BQ065272 | lymph, lymphoma, cell line | .j | 1 to 670 | 1 to 673 | exact | tiling clone, | 673/1188 (56 %) | 9 diff (99.3 %id) | |
BQ065272 | lymph, lymphoma, cell line | .j | 1 to 670 | 1 to 673 | exact | tiling clone, | 673/1188 (56 %) | 9 diff (99.3 %id) | |
BU502486 | carcinoma, cell line, Prostate | .g | 23 to 568 | 90 to 641 | 552/1264 (43 %) | 30 diff (97.7 %id) | |||
BU502486 | carcinoma, cell line, Prostate | .g | 23 to 568 | 90 to 641 | 552/1264 (43 %) | 30 diff (97.7 %id) | |||
BQ958807 | carcinoma, cell line, Prostate | .g | 3 to 811 | 1 to 820 | 820/876 (93 %) | 13 diff (98.6 %id) | |||
BQ958807 | carcinoma, cell line, Prostate | .g | 3 to 811 | 1 to 820 | 820/876 (93 %) | 13 diff (98.6 %id) | |||
NM_025049.2 | .c | 30 to 2688 | 1 to 2659 | exact | RefSeq, | 2659/2659 (100 %) | 1 diff (100.0 %id) | ||
DA997599 | .a | 426 to 813 | 2 to 389 | capped | 388/388 (100 %) | 1 diff (99.8 %id) | |||
DN998093 | breast cancer, Mammary gland (cancer tissue) | .i | 1 to 673 | 8 to 680 | exact | tiling clone, | 673/680 (98 %) | 6 diff (99.2 %id) | |
DN998093 | breast cancer, Mammary gland (cancer tissue) | .i | 1 to 673 | 8 to 680 | exact | tiling clone, | 673/680 (98 %) | 6 diff (99.2 %id) | |
DN999504 | .a | 65 to 630 | 12 to 577 | 566/577 (98 %) | 6 diff (99.0 %id) | ||||
TI_154166449 | .e | 1136 to 1632 | 93 to 590 | 498/953 (52 %) | 5 diff (99.5 %id) | ||||
CA310274 | Alveolar Macrophage, lung | .l-u | 184 to 833 | 665 to 16 | exact | tiling clone, AAA | Possibly primed on the genome, locally A rich (24/24 A in genome downstream of last aligned base) | 650/651 (99 %) | 3 diff (99.6 %id) |
CA310274 | Alveolar Macrophage, lung | .l-u | 184 to 833 | 665 to 16 | exact | tiling clone, AAA | Possibly primed on the genome, locally A rich (24/24 A in genome downstream of last aligned base) | 650/651 (99 %) | 3 diff (99.6 %id) |